Drug-Eluting Stents

The aim of this collection of activities is to help clinicians distill the data comparing the efficacy and safety of the various types of drug-eluting stents (DES). These activities will also address the appropriate use of percutaneous coronary intervention (with DES or bare metal stents) vs bypass surgery in complex patients in need of coronary revascularization.

Thrombus Aspiration: A TASTE of Things to Come CME
Is there a role for thrombus aspiration in patients undergoing primary PCI? Drs Byrne, Götberg, Jolly, and Kirtane review the data.
December 5, 2013
Antiplatelet Therapy After PCI: A Global Perspective CME
The optimal duration of DAPT is uncertain. Dr Kandzari reviews the data, and Drs Abizaid, Chen, Montalescot, Nakamura, and Sabate comment.
August 9, 2013
An Elderly Man With AF and a Bifurcation Lesion CME
Dr Latib presents a seemingly typical bifurcation case to Dr Simon and provides tips on what to do when you run into trouble.
December 21, 2012
Bifurcation Stenting in a Patient With Prior CABG CME
Dr Burzotta presents a tricky case to Dr Hildick-Smith that covers SVG lesions, the TAP technique, and tackling trifurcations.
December 21, 2012

Carlo Di Mario, MD
Professor of Clinical Cardiology, Imperial College, Consultant Cardiologist, Royal Brompton Hospital, London, United Kingdom
Fausto Feres, MD, PhD
Interventional Cardiology Department, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
David E. Kandzari, MD
Director, Interventional Cardiology, Chief Scientific Officer, Piedmont Heart Institute, Atlanta, Georgia

Hyo-Soo Kim, MD, PhD
Director, Cardiac Catheterization Laboratory & Coronary Intervention; Director, National Research Laboratory for Cardiovascular Stem Cell Niche; Professor, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
Sunil V. Rao, MD
Associate Professor of Medicine, Duke University Medical Center, Director, Cardiac Catheterization Laboratories, Durham VA Medical Center, Durham, North Carolina
Daniel I. Simon, MD
Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve University School of Medicine, Director, Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Cleveland, Ohio

Supported by an independent educational
grant from

Downloadable Slide Kit

Key DES and PCI Trials of 2012
Top-line findings from some of the influential trials on DES and PCI from 2012.
Key Adjunctive Pharmacology Trials in 2012
Top-line findings from some of the major trials on adjunctive pharmacology related to PCI and ACS management from 2012.
ARC Definitions of Stent Thrombosis
A brief overview of the ARC definitions of stent thrombosis.

Clinical Articles

Steering Committee

Carlo Di Mario, MD, PhD

Carlo Di Mario, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Covidien; St. Jude Medical
Served as a speaker or a member of a speakers bureau for: Cordis Corporation; St. Jude Medical; Boston Scientific; Medtronic, Inc.; Eli Lilly and Company
Received grants for clinical research from: Abbott Laboratories; Medtronic, Inc.; BioSensors International Group,Ltd.; Micell Technologies, Inc.

Fausto Feres, MD, PhD

Fausto Feres, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Medtronic, Inc.; sanofi-aventis
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; Medtronic, Inc.; sanofi-aventis; Terumo Medical Corporation

David E. Kandzari, MD

David E. Kandzari, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic, Inc.; Abbott Laboratories; Covidien; Medtronic, Inc.; Cordis Corporation; Micell Technologies, Inc.
Received grants for clinical research from: Abbott Laboratories; Medtronic, Inc.

Hyo-Soo Kim, MD, PhD

Hyo-Soo Kim, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boston Scientific; Eli Lilly and Company; Merck Sharp & Dohme Corp.
Received grants for clinical research from: Abbott Laboratories; Boston Scientific; Medtronic, Inc.; Pfizer Inc

Sunil V. Rao, MD

Sunil V. Rao, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; sanofi-aventis; The Medicines Company;
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; sanofi-aventis; Terumo Medical Corporation; The Medicines Company
Received grants for clinical research from: Cordis Corporation; Ikaria, Inc.; sanofi-aventis

Daniel I. Simon, MD

Daniel I. Simon, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Cordis Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Medtronic, Inc.; Merck & Co., Inc.
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories

	What is your antiplatelet strategy post-PCI or MI in patients on oral anticoagulation (OAC) in light of the WOEST trial?
		Clopidogrel and OAC
		Aspirin and OAC
		Triple therapy
		Triple therapy for the first 3 months, then dual therapy